RxDoctor Payments DataLook up a doctor →

Francisco Velazquez, MD

Internal Medicine · Bellaire, TXNPI 1922096197

Payments from drug & device makers

$11,635,388in general payments, 2019–2025

Across 1,358 payments — averaging $8568.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$8.1M
  • Regeneron$1M
  • Novartis$770K
  • AbbVie$696K
  • Astellas Pharma Global Development$646K
  • Ironwood Pharmaceuticals, Inc$90K
  • plus $275K from 37 others

What the payments were for

  • Travel & lodging$62614%
  • Food & beverage$3,95786%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,635,388 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$19,640
Medicare patients
56
Services billed
237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$58,681
CreonLipase/Protease/Amylase14$34,243
DescovyEmtricitabine/Tenofov Alafenam12$25,899
FarxigaDapagliflozin Propanediol17$18,641
MyrbetriqMirabegron19$12,134
PaxlovidNirmatrelvir/Ritonavir15$1,429
Tamsulosin Hcl40$1,207
SynthroidLevothyroxine Sodium12$728
Rosuvastatin Calcium70$703
Desvenlafaxine Succinate ErDesvenlafaxine Succinate14$672
Atorvastatin Calcium67$659
Quetiapine Fumarate23$628
Metoprolol Succinate39$615
Bupropion XlBupropion Hcl13$600
Olmesartan Medoxomil25$536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya, Descovy$484$84,58025 claims
AbbVieCreon, Synthroid$695,614$34,97126 claims
AstraZenecaFarxiga$22,312$18,64117 claims
Astellas Pharma US IncMyrbetriq$14$12,13419 claims
PfizerPaxlovid$8,720$1,42915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Bellaire

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →